Pozen enrolling for Phase III study of heart drug
Pozen
On The Web
Site Search
Get the latest news alerts: Follow LTW at Twitter
Local Tech Wire
CHAPEL HILL, N.C. — Pozen Inc. (NASDAQ: POZN) said Friday that it has begun enrolling 1,000 patients across the country for two Phase III studies for its experimental drug for use in the secondary prevention of heart attacks and strokes in patients at risk for associated gastric ulcers.
The compound, PA32540, is a fixed-dose combination of 325 mg of enteric-coated aspirin and 40 mg of immediate-release omeprazole.
The two trials will operate under a special protocol assessment that Pozen and the federal Food and Drug Administration set up, Pozen said. The studies will involve over 100 sites, enrolling approximately 500 patients per study.
“We believe that PA32540 could address the needs of certain patients with cardiovascular disease,” said Dr. John Fort, Pozen's chief medical officer.
Copyright 2010 Local Tech Wire. All rights reserved.
Featured
Hot Off The Wire
- Hot Off the Wire – Google phone now runs on AT&T network; Microsoft told to pay $106M in patent dispute; Bing gains market share
- Hot Off the Wire – Maryland firm BroadSoft files for IPO; Twitter preps China page; John Grisham’s Firm, other titles now e-books
- Hot Off the Wire – Apple charges $107 for iPad batteries; Amazon drops Colorado affiliates like it did in N.C.; Facebook expands in India
E-mail Preferences
The Skinny
- N.C. fund is good news for state's tech entrepreneurs
- Another 202 layoffs at IBM push latest count above 2,900
- ‘Social media is a beast’ – So how can your business tame it?
- In tough climate, GSK dedicates plant to fight elephantiasis
- ‘Who’s Cisco?’ New RTP site exec recalls a humble birth
- Google, N.C.? UNC-CH, Carrboro, Chapel Hill want Google Net
- Tweet this from Epic: Three more hints about Gears 3
- ‘The Daily Me’: You want your news mobile, instantly from several sources
- ‘Gears 3’ rumors grow louder – Epic president dropping hints
- Intel-ligent boost for tech – Intel, VCs launch investment alliance